Open Label Study of TRx0014 in Alzheimer's Disease
Status:
Completed
Trial end date:
2010-12-02
Target enrollment:
Participant gender:
Summary
This is an open label, dose-ranging study of two doses of TRx0014 in patients with mild or
moderate Alzheimer's Disease. The trial is made available to any patient ongoing on treatment
in the clinical trial designated TRx-014-001 at termination of that study. Treatment for each
individual patient will continue for as long as the treating physician feels there is benefit
to the patient. This current protocol covers each patient for 12 months in the first
instance.